Preservation of Hirdin Antithrombin Activity in a Low-Water-Activity Solid Premix: Formulation Performance and the Human Pharmacodynamic Context of Direct Thrombin Inhibition

Anas Ziraoui; Thabo Mokoena; Halima Hassan

doi:10.51699/0dss7w94

Authors

Anas Ziraoui National Standards Laboratory SA, Chemin des Orlons 10, CH-1860 Aigle, Switzerland
Thabo Mokoena National Standards Laboratory SA, Chemin des Orlons 10, CH-1860 Aigle, Switzerland
Halima Hassan National Standards Laboratory SA, Chemin des Orlons 10, CH-1860 Aigle, Switzerland

DOI:

https://doi.org/10.51699/0dss7w94

Keywords:

Hirudin, Direct Thrombin Inhibitor, Antithrombin Activity, Water Activity, Peptide Stabilization, Solid Premix, Anticoagulation

Abstract

Hirudin is a specific direct thrombin inhibitor, and its use depends on retaining conformational integrity and antithrombin activity. We characterized a dry solid premix developed to stabilize hirudin during powder processing and unit-dose filling. Formulation results were considered alongside published human pharmacodynamic studies of recombinant hirudin. The BCLC® premix used trehalose, mannitol and colloidal silicon dioxide for preadsorptive dispersion; citric acid-sodium citrate for local pH control; microcrystalline cellulose and pregelatinized starch as a low-hygroscopicity matrix; and geometric dilution under low humidity. Water activity was 0.26-0.34 in the three optimized formulations. Activity retention was 90.6-92.1%, activity-distribution RSD was 3.8-4.7%, and capsule fill-weight RSD was 2.9-3.4%. Retained activity fell to 76.4% without protective dispersion and staged dilution, 72.9% during high-humidity processing, and 80.1% without the buffer. Intravenous and subcutaneous studies of recombinant hirudin report dose-related prolongation of thrombin time and activated partial thromboplastin time. These pharmacodynamic findings define biomarkers for later studies of stabilized hirudin systems.

References

[1] K. L. Kaplan and C. W. Francis, “Direct thrombin inhibitors,” Semin. Hematol., vol. 39, no. 3, pp. 187–196, 2002, PMID: 12124681.

[2] P. H. Johnson, “Hirudin: Clinical potential of a thrombin inhibitor,” Annu. Rev. Med., vol. 45, pp. 165–177, 1994, PMID: 8198374.

[3] A. Greinacher and T. E. Warkentin, “The direct thrombin inhibitor hirudin,” Thromb. Haemost., vol. 99, no. 5, pp. 819–829, 2008, PMID: 18449411.

[4] Direct Thrombin Inhibitor Trialists’ Collaborative Group, “Direct thrombin inhibitors in acute coronary syndromes,” Lancet, vol. 359, no. 9303, pp. 294–302, 2002, PMID: 11830196.

[5] F. Schiele et al., “Subcutaneous recombinant hirudin versus intravenous sodium heparin in established acute deep vein thrombosis,” Thromb. Haemost., vol. 77, no. 5, pp. 834–838, 1997, PMID: 9184388.

[6] B. I. Eriksson et al., “A comparison of recombinant hirudin with a low-molecular-weight heparin after total hip replacement,” N. Engl. J. Med., vol. 337, no. 19, pp. 1329–1335, 1997, doi: 10.1056/NEJM199711063371901.

[7] The OASIS-2 Investigators, “Effects of recombinant hirudin compared with heparin in acute myocardial ischaemia without ST elevation,” Lancet, vol. 353, no. 9151, pp. 429–438, 1999, PMID: 9989712.

[8] P. Eichler et al., “Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin,” Blood, vol. 96, no. 7, pp. 2373–2378, 2000, PMID: 11001886.

[9] A. Greinacher et al., “Anaphylactic and anaphylactoid reactions associated with lepirudin,” Circulation, vol. 108, no. 17, pp. 2062–2065, 2003, PMID: 14568897.

[10] X. Xu et al., “Self-regulated hirudin delivery for anticoagulant therapy,” Sci. Adv., vol. 6, no. 41, 2020, PMID: 33036973.

[11] Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, Hoet B, Bichler J, Close P, “Biologic effects of recombinant hirudin (CGP 39393) in human volunteers,” J Am Coll Cardiol. 1993,22(4):1080-1088. doi:10.1016/0735-1097(93)90419-2.

[12] Schenk JF, Glusa E, Radziwon P, Butti A, Markwardt F, Breddin HK, “A recombinant hirudin (IK-HIR02) in healthy volunteers,” I. Effects on coagulation parameters and bleeding time. Haemostasis. 1996,26(3):140-149. doi:10.1159/000217199.

[13] Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H, “Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers,” Thromb Haemost. 1997,77(5):911-919. doi:10.1055/s-0038-1656077.

[14] Topol EJ, Fuster V, Harrington RA, et al, “Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial,” Circulation. 1994,89(4):1557-1566. doi:10.1161/01.CIR.89.4.1557.

[15] Cen X, Ni J, Tan T, et al, “Investigation on recombinant hirudin via oral route,” Peptides. 2006,27(4):836-840. doi:10.1016/j.peptides.2005.08.015.